Alopecia Areata: Causes, Symptoms, Triggers & Treatment

What Is Alopecia Areata?

Alopecia areata (AA) is an autoimmune disease that causes sudden, non-scarring hair loss in discrete patches. Unlike scarring alopecias that permanently destroy the follicle, alopecia areata spares the follicle itself — the hair bulb remains intact below the scalp surface, and regrowth is biologically possible at any stage of the disease.

It is one of the most common autoimmune conditions, with a lifetime prevalence of approximately 2% globally and roughly 1 in 50 to 1 in 100 people affected at some point in their lives. It occurs across all ages, sexes, and skin tones, though it is somewhat more frequent in females with late-onset disease and is associated with higher rates in Asian, Black, and Hispanic populations.

How Alopecia Areata Develops: The Science

Loss of Immune Privilege

Healthy, actively growing (anagen) hair follicles are one of the few sites in the body that exist in a state of immune privilege — a form of protected status that prevents the immune system from recognizing and attacking follicle-specific proteins. This privilege is maintained by a combination of anti-inflammatory signals including TGF-β, α-melanocyte-stimulating hormone (α-MSH), and reduced expression of MHC class I molecules.

In alopecia areata, this privilege collapses. The trigger — which may be viral infection, psychological stress, vaccination, or remain unknown — disrupts these protective signals and upregulates MICA (MHC class I chain-related protein A) on follicular cells. This activates natural killer (NK) cells and autoreactive CD8+ T cells, which infiltrate the hair follicle in a characteristic histological pattern called the "bee-swarm" — a dense perifollicular lymphocytic infiltrate.

The JAK-STAT Cascade

Once inside the follicle microenvironment, these immune cells release interferon-gamma (IFN-γ) and interleukin-15 (IL-15). Both cytokines signal through the JAK-STAT pathway:

• IFN-γ activates JAK1 and JAK2
• IL-15 activates JAK1 and JAK3

The resulting STAT1 and STAT3 phosphorylation amplifies the inflammatory response and prematurely pushes anagen follicles into the catagen and telogen phases — causing the hair to shed. Because the follicle is not destroyed, it retains the capacity to re-enter anagen once the immune attack subsides. This mechanism is precisely why JAK inhibitors — which block the signals that perpetuate the attack — have emerged as the most targeted therapy for severe disease.

Genetic Architecture

At least 16 genetic susceptibility loci have been confirmed, including HLA class I and II alleles and genes regulating immune responses (CTLA4, IL2RA, PTPN22), hair pigmentation, and oxidative stress. A positive family history is present in approximately 10–20% of patients. The condition does not follow simple Mendelian inheritance; environmental factors clearly contribute.

Subtypes of Alopecia Areata

Signs and Symptoms

Hair Loss Characteristics

The most recognized presentation is one or more smooth, round or oval bald patches, appearing suddenly — often noticed by a family member or during a haircut before the person is aware of it. The skin within the patch appears normal: no redness, no scarring, no scaling.

Several additional features may be present:

• Exclamation-mark hairs: Short, broken hairs that are thinner at the base than the tip — shaped like an exclamation point (!) — at the periphery of active patches. These represent the hair shaft being damaged as the follicle arrests in anagen. They are pathognomonic of active alopecia areata and are best visualized with dermoscopy.
• Yellow dots and black dots: Dermoscopic signs of follicular openings with trapped sebum (yellow dots, indicating follicles entering telogen) or pigment casts of broken hair shafts (black dots), markers of active disease.
• Positive hair pull test: More than 10% of grasped hairs detach easily at the patch margin, indicating active anagen arrest.
• Tingling or burning: Some people notice itching, tingling, or mild scalp sensitivity in an area before visible hair loss appears.

Hair may regrow initially without pigment — white or gray — because the melanocytes within the follicle are also targeted by the autoimmune attack. Pigmentation usually returns with subsequent growth cycles.

Nail Involvement

Up to 10–40% of people with alopecia areata develop nail changes, which correlate with disease severity. Nail manifestations include:

• Pitting — rows of small punctate dents across the nail surface (the most common finding)
• Trachyonychia — rough, opaque, ridged nails ("twenty-nail dystrophy")
• Beau's lines — transverse depressions indicating arrest of nail matrix growth
• Koilonychia — "spoon nails" (scooped upward curvature)
• Onychorrhexis — longitudinal ridging and brittleness

Nail pitting can occasionally precede scalp hair loss and serves as a useful early diagnostic sign.

Eyebrow and Eyelash Loss

AA can affect any hair-bearing area. Eyebrow loss is typically patchy and bilateral; eyelash loss (madarosis) can significantly affect daily life and self-image. These sites are now specifically addressed in JAK inhibitor trial endpoints.

Triggers

Environmental triggers that may precipitate an episode in genetically susceptible individuals include:

• Acute psychological stress — among the most commonly reported triggers
• Viral infections — Epstein-Barr virus, hepatitis C, influenza
• Vaccination (rarely documented)
• Physical injury to the scalp
• Hormonal shifts (pregnancy, postpartum)

In many patients, no specific trigger is identified.

Comorbidities

People with alopecia areata have a statistically elevated risk of co-occurring autoimmune and atopic conditions:

• Thyroid disease (Hashimoto's thyroiditis, Graves' disease) — screen with TSH at diagnosis
• Atopic dermatitis — present in 25–40% of AA patients; associated with poorer prognosis
• Vitiligo — shares the immune privilege collapse mechanism
• Psoriasis
• Lupus erythematosus
• Type 1 diabetes
• Allergic rhinitis and asthma

Rates of anxiety and depression are significantly elevated — alopecia areata carries a substantial psychological burden, and mental health support is a legitimate and important component of care.

Treatment

Treatment selection depends on the extent of hair loss, patient age, and disease activity. Because the underlying autoimmune process is not yet curable, the goal is remission — restoring hair while the condition is suppressed — rather than permanent cure.

For Limited Patchy Disease (Adults)

Intralesional corticosteroid injections remain the most evidence-supported first-line treatment for adults with a few patches of hair loss.

• Drug: triamcinolone acetonide, typically 5–10 mg/mL
• Schedule: every 4–6 weeks
• Efficacy: 60–67% of patients achieve some regrowth within 3 months; one AAD-cited study of 127 patients found more than 80% achieved at least 50% regrowth by 12 weeks
• Limitations: not suitable for very large areas; can cause local skin atrophy if administered too superficially

Topical corticosteroids (e.g., clobetasol 0.05% solution or foam) are an alternative for patients who decline injections or for treating children. Occlusive application improves penetration.

Minoxidil (topical 2–5% solution; oral low-dose) does not treat the autoimmune cause but may stimulate follicular cycling in partially responding follicles. It is typically combined with other treatments rather than used alone.

For Extensive Disease or Treatment-Resistant Patchy Disease

Contact immunotherapy (DPCP/SADBE): Diphenylcyclopropenone (DPCP) or squaric acid dibutylester (SADBE) is applied weekly to the scalp, deliberately sensitizing and then re-exposing to induce a controlled contact dermatitis. This is thought to redirect the autoimmune infiltrate away from follicles. Efficacy varies: reported response rates range from 17% to 74.6% for patchy disease. Side effects include severe local dermatitis, cervical lymphadenopathy, and pigment changes.

Oral JAK inhibitors (FDA-approved): The most significant therapeutic advance in decades.

All three carry FDA Boxed Warnings for serious infections, malignancy (including lymphoma and lung cancer), major adverse cardiovascular events (MACE), and thrombosis — risks shared across the JAK inhibitor class. Long-term safety data are still accumulating. A critical limitation: hair loss typically recurs within weeks to months of discontinuation, meaning patients may require prolonged treatment.

Systemic corticosteroids (pulse methylprednisolone or oral prednisone) can produce rapid regrowth but are not used long-term due to systemic side effects. They are occasionally used to bridge to JAK inhibitor therapy.

Methotrexate — typically combined with low-dose oral corticosteroids — has been studied in retrospective series with complete response rates of approximately 45%; it is an off-label option for extensive disease when JAK inhibitors are inaccessible.

For Children (Under 12)

• Topical corticosteroids and intralesional injections (for children over 10 who can tolerate them) are standard
• Ritlecitinib is approved for patients aged 12 and older — the only JAK inhibitor with adolescent approval
• DPCP/SADBE contact immunotherapy may be considered under specialist supervision

Cosmetic and Psychological Support

Because alopecia areata is not medically dangerous, and because spontaneous remission is always possible, quality-of-life support is as important as pharmacological treatment:

• Medical-grade wigs and hairpieces (often covered by insurance or healthcare systems where available)
• Eyebrow microblading/tattooing, false eyelashes
• Scalp micropigmentation
• Mental health support, CBT, and access to peer communities (the National Alopecia Areata Foundation provides resources and support groups)

Prognosis

Alopecia areata's course is inherently unpredictable.

• In limited patchy disease, approximately 34–50% of patients experience spontaneous remission within one year — though most will have at least one further episode
• Placebo-controlled trial data (the most rigorous estimate) show meaningful spontaneous hair regrowth (SALT30) in only approximately 8.2% of patients, suggesting that apparent spontaneous recovery in clinical series may partially reflect the natural fluctuating course rather than true stable remission
• Alopecia totalis and universalis carry significantly poorer prognoses: only 9–18% achieve complete or near-complete spontaneous regrowth in long-term follow-up

Poor prognostic factors (associated with lower chance of sustained regrowth):

• Ophiasis pattern
• Disease onset before puberty
• Family history of alopecia areata
• Concurrent atopic dermatitis
• Nail involvement
• Duration of hair loss >1 year before treatment
• Prior episodes of alopecia totalis or universalis

Hair follicles in alopecia areata are never permanently destroyed — this is the critical distinction from scarring alopecias. Regrowth potential is maintained for decades and is possibly lifelong.

When to See a Dermatologist

Alopecia areata can closely resemble other causes of hair loss — particularly tinea capitis (scalp ringworm), trichotillomania, and diffuse alopecia areata can be confused with female-pattern hair loss. A board-certified dermatologist can confirm the diagnosis via clinical examination, dermoscopy, and scalp biopsy when needed.

See a dermatologist promptly if:

• You notice sudden bald patches, particularly if smooth and non-itchy
• Hair loss extends to eyebrows, eyelashes, or body hair
• You have nail pitting or changes alongside hair loss
• Hair loss is spreading rapidly or covering a large area of the scalp
• You have previously been diagnosed with alopecia areata and are experiencing a new episode
• Hair loss is significantly affecting your mental health, work, or daily life

Early intervention — particularly with JAK inhibitors for extensive disease — is associated with better outcomes.